Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics
Nabriva Therapeutics plc - Ordinary Shares (NBRV)
Today's Latest Price: $1.82 USD
0.05 (-2.67%)
Updated Dec 6 1:11pm
Add NBRV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NBRV Stock Summary
- NBRV's price/sales ratio is 420.89; that's higher than the P/S ratio of 99.37% of US stocks.
- With a year-over-year growth in debt of 4,005.74%, Nabriva Therapeutics plc's debt growth rate surpasses 98.77% of about US stocks.
- Revenue growth over the past 12 months for Nabriva Therapeutics plc comes in at -68.27%, a number that bests merely 2.11% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Nabriva Therapeutics plc, a group of peers worth examining would be KDMN, GERN, ADVM, PRTA, and NYMX.
- NBRV's SEC filings can be seen here. And to visit Nabriva Therapeutics plc's official web site, go to www.nabriva.com.
NBRV Daily Price Range
NBRV 52-Week Price Range
NBRV Stock Price Chart More Charts
NBRV Price/Volume Stats
| Current price | $1.82 |
| Prev. close | $1.87 |
| Day low | $1.80 |
| Day high | $1.89 |
| 50-day MA | $1.92 |
| 200-day MA | $2.27 |
| 52-week high | $3.27 |
| 52-week low | $1.12 |
| Volume | 663,451 |
| Avg. volume | 1,076,136 |
| Dividend yield | N/A |
| Market Cap | 1.43B |
Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio
Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.
Top Stories View All
Why I’m Bearish On Disney (DIS) in the Short-term
Best & Worst Performing Stock Industries for December 5, 2019
Best & Worst Performing Small Cap Stocks for December 5, 2019
Best & Worst Performing Mid Cap Stocks for December 5, 2019
Best & Worst Performing Large Cap Stocks for December 5, 2019
View All Top Stories
Loading social stream, please wait...